It is very uncertain whether comparison 3: anticonvulsant levetiracetam changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
It is very uncertain whether comparison 4: antipsychotics changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
It is very uncertain whether comparison 5: benzodiazepines changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
It is very uncertain whether comparison 1: 5HT1A partial agonists changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
It is very uncertain whether comparison 8: NARIs changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
It is very uncertain whether comparison 9: NaSSAs changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
It is very uncertain whether comparison 10: RIMAs changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
Comparison 12: SNRIs probably leads to higher dropouts due to adverse events (acute phase) compared with placebo (moderate certainty).
It is very uncertain whether comparison 2: anticonvulsants/GABAs changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
Comparison 13: SSRIs may leads to higher dropouts due to adverse events (acute phase) compared with placebo (low certainty).
Comparison 14: GW876008 showed no clear difference in dropouts due to adverse events (acute phase) compared with placebo (low certainty).
It is very uncertain whether comparison 5: SNRIs changes treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (very low certainty).
Comparison 6: SSRIs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (moderate certainty).
Comparison 7: TCAs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (moderate certainty).
Comparison 1: Alpha‐blockers showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (moderate certainty).
Comparison 2: Antipsychotics showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (low certainty).
Comparison 3: MAOIs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (low certainty).
Comparison 4: NaSSAs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (low certainty).